Cosmos Health Strengthens Global Brain Tumor Market Position by Entering Agreement to Acquire Remaining Rights to WIPO-Filed CNS Cancer Drug Patent
Cosmos Health (NASDAQ:COSM) announced its agreement to acquire the remaining rights to a CNS cancer drug patent filed with WIPO under PCT/EP2023/071865. This acquisition follows the December 2023 agreement where Cosmos Health had secured 60% of the rights. The National Hellenic Research Foundation, a major Greek research entity, will continue supporting Cosmos Health during the transition. This move aims to bolster Cosmos Health's position in the global brain tumor treatment market, projected to grow from $3.1 billion in 2023 to $6.2 billion by 2033. CEO Greg Siokas highlighted the importance of this acquisition in addressing the rising incidence of CNS cancers and the needs of the aging population. This initiative is complemented by recent hires and the strategic acquisition of Cloudpharm to enhance R&D capabilities with AI-aided drug repurposing technologies.
- Cosmos Health has secured full rights to a CNS cancer drug patent.
- The global brain tumor treatment market is projected to grow from $3.1 billion in 2023 to $6.2 billion by 2033.
- The National Hellenic Research Foundation will continue to support Cosmos Health.
- Cosmos Health aims to revolutionize pharmaceutical products through AI-aided drug repurposing technologies.
- The press release does not mention any immediate revenue generation from the acquired patent.
- There may be significant R&D and commercialization costs associated with the newly acquired patent.
Insights
The acquisition of full rights to a CNS cancer drug patent is a significant milestone for Cosmos Health, especially in the context of the projected growth in the global brain tumor treatment market. The market is expected to grow from
From a financial perspective, this move could enhance the company’s revenue streams in the long term. The investment in proprietary R&D and strategic acquisitions, such as that of Cloudpharm, indicates a strong commitment to innovation, which is important in the pharmaceutical industry. Additionally, acquiring the remaining 40% of the patent rights ensures that Cosmos Health retains complete control over the commercialization and potential royalty streams of the drug.
However, investors should be cautious about the upfront costs associated with such acquisitions and the long timelines for drug development and approval. The success of this venture will ultimately depend on the drug’s clinical efficacy, regulatory approvals and market adoption.
In the short term, this acquisition might not drastically impact the company’s financials, but it aligns with a long-term growth strategy that could yield substantial returns if the drug proves successful.
Acquiring the full rights to a CNS cancer drug patent is a strategic move for Cosmos Health, particularly given the rising incidence of brain tumors and the aging population. CNS cancers are notoriously challenging to treat and if this drug proves effective, it could become a critical part of the treatment landscape.
The involvement of the National Hellenic Research Foundation, a reputable institution, adds credibility to the drug’s development process. Their continued support suggests a strong foundation in the drug’s initial research phases. However, the transition from research to commercialization involves numerous hurdles, including extensive clinical trials, regulatory approvals and market acceptance.
Investors should understand that the drug development process is lengthy and uncertain. While the potential market is significant, the success of the drug will depend on its performance in clinical trials and its ability to meet regulatory standards. The integration of AI-aided drug repurposing technologies is promising, as it may expedite the development process, but it does not guarantee success.
The brain tumor treatment market is poised for substantial growth, doubling in size over the next decade. Cosmos Health’s acquisition of the full rights to a CNS cancer drug patent positions it strategically within this expanding market.
It's important to note that the market dynamics for brain tumor treatments are influenced by several factors, including the rising incidence of these cancers and the aging population. This acquisition aligns well with these trends and could provide Cosmos Health with a competitive edge if the drug can be successfully brought to market.
However, the competitive landscape in oncology is intense. Numerous companies are vying for market share with innovative treatments. Cosmos Health will need to differentiate its product through superior efficacy, safety profiles and cost-effectiveness. The company's focus on AI-aided drug repurposing technology may offer a unique advantage, potentially speeding up the development process and reducing costs.
For investors, this acquisition shows Cosmos Health’s commitment to innovation and market leadership. While there are risks associated with the development and regulatory processes, the potential rewards in the growing brain tumor treatment market are substantial.
CHICAGO, IL / ACCESSWIRE / June 18, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has entered into an agreement to acquire all remaining rights arising from the patent filed with the World Intellectual Property Organization (WIPO) under reference code PCT/EP2023/071865. This follows the agreement announced on December 7, 2023, where Cosmos Health had acquired
One of the sellers, the prestigious National Hellenic Research Foundation, founded in 1958, is among the largest research centers in Greece. As a non-profit organization supervised by the General Secretariat for Research and Innovation (GSRI) of the Ministry of Development, the foundation has played a crucial role in the development phase. It will continue to support Cosmos Health as it transitions to sole ownership and pursues its commercial objectives.
Acquiring full rights to the patent is expected to enhance Cosmos Health's role in the global brain tumor treatment market, which, according to Future Market Insights, is projected to double from
Greg Siokas, Chief Executive Officer of Cosmos Health, stated: "We are thrilled to have entered into an agreement to acquire full rights to what we believe is a groundbreaking treatment for CNS cancers, focusing on brain tumor-related issues. This acquisition comes at a crucial time when the rising incidence of these cancers and the growing geriatric population highlight the urgent need for effective solutions. We expect to accelerate our initiatives in the R&D space, fueled by our recent hiring of best-in-class scientists and our strategic acquisition of Cloudpharm, enabling us to revolutionize pharmaceutical products through AI-aided, advanced drug repurposing technologies. This approach allows us to deliver medicines faster and more efficiently. We would also like to thank the exceptional team at the National Hellenic Research Foundation for their continued support."
About the Patent on Drug Targeting CNS Cancers:
The patent filing describes the repurposing of an existing drug to act on the Mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), a key target in various diseases. This innovation proposes the use of the repurposed drug in addressing certain central nervous system (CNS) cancers, hematological cancers, allergic inflammation, and autoimmune diseases. Existing preclinical data are promising for the further development of these findings:
Figure: The repurposed MALT1 inhibitor's effect on Glioblastoma Multiforme spheroids: untreated (left), treated (right). MALT1-dependent inhibition leads to cell death.
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe® and C-Sept®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency, it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic and the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
+44 207 0971 653
SOURCE: Cosmos Health Inc.
View the original press release on accesswire.com
FAQ
What recent agreement did Cosmos Health (NASDAQ:COSM) announce?
How will the recent acquisition affect Cosmos Health's market position?
Who is supporting Cosmos Health in the transition to full ownership of the CNS cancer drug patent?
What is the projected growth rate of the global brain tumor treatment market?
What technologies is Cosmos Health using to enhance its R&D capabilities?
